---
title: "ZBIO.US (ZBIO.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ZBIO.US/news.md"
symbol: "ZBIO.US"
name: "ZBIO.US"
parent: "https://longbridge.com/en/quote/ZBIO.US.md"
datetime: "2026-05-20T11:58:52.020Z"
locales:
  - [en](https://longbridge.com/en/quote/ZBIO.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ZBIO.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ZBIO.US/news.md)
---

# ZBIO.US (ZBIO.US) — Related News

### [Tuesday 5/19 Insider Buying Report: ZBIO, ICFI](https://longbridge.com/en/news/286954937.md)
*2026-05-19T18:50:16.000Z*
> On May 19, Zenas Biopharma's CEO Leon O. Moulder Jr. purchased 60,000 shares of ZBIO for $1.01M, seeing a 7.6% gain as t

### [Zenas BioPharma To Present INDIGO Phase 3 Data At EULAR 2026; Wedbush Sees $45 Target](https://longbridge.com/en/news/286916856.md)
*2026-05-19T12:55:24.000Z*
> Zenas BioPharma will present Phase 3 INDIGO trial results for Obexelimab at EULAR 2026, showing a 56% reduction in IgG4-

### [Zenas BioPharma Insider Bought Shares Worth $1,012,800, According to a Recent SEC Filing](https://longbridge.com/en/news/286872009.md)
*2026-05-19T07:28:00.000Z*
> Leon O Moulder Jr, CEO of Zenas BioPharma, purchased 60,000 shares for $1,012,800 on May 18, 2026. Following this transa

### [Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress | ZBIO Stock News](https://longbridge.com/en/news/286900519.md)
*2026-05-19T03:05:34.000Z*
> Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Imm

### [Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://longbridge.com/en/news/286816109.md)
*2026-05-18T20:16:22.000Z*
> Zenas BioPharma, Inc. announced the granting of 51,075 restricted stock units to new employees as an inducement for join

### [How Zenas BioPharma’s First-in-Human Oral IL-17 Trial Could Reframe Zenas BioPharma (ZBIO) Investors](https://longbridge.com/en/news/286517927.md)
*2026-05-15T06:24:13.000Z*
> Zenas BioPharma has initiated a Phase 1 trial for ZB021, an oral IL-17AA/AF inhibitor, with results expected by late 202

### [Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor | ZBIO Stock News](https://longbridge.com/en/news/286245469.md)
*2026-05-13T02:50:35.000Z*
> Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Ora

### [Zenas BioPharma, Inc. 1Q 2026: Revenue $16.91M, EPS ($1.46) — 10-Q Summary](https://longbridge.com/en/news/286244202.md)
*2026-05-13T10:41:00.000Z*
> Zenas BioPharma, Inc. reported Q1 2026 revenue of $16.91M, up 69.1% from $10M a year ago, but incurred a net loss of $80

### [Zenas BioPharma Highlights Strong Q1 Progress and Financing](https://longbridge.com/en/news/286243392.md)
*2026-05-13T10:34:53.000Z*
> Zenas BioPharma, Inc. reported significant progress in Q1 2026, including the approval of two Class II directors and the